<DOC>
	<DOCNO>NCT01955681</DOCNO>
	<brief_summary>This retrospective , non-interventional , multicenter , observational chart review study explore clinical benefit retreatment TKI real world .</brief_summary>
	<brief_title>A Retrospective , Non-interventional , Multicenter , Observational Chart Review Study Explore Clinical Benefits Retreatment With TKI Real World .</brief_title>
	<detailed_description>This study design retrospectively review medical chemotherapy record 300 patient EGFR mutation positive adenocarcinoma NSCLC . Eligible patient follow : histologically cytologically confirm NSCLC , undergone EGFR-TKI retreatment sometime failure initial EGFR-TKI . After initial treatment , patient treat chemotherapy subsequently re-treated EGFR-TKI identified . The target population derive multicentre Taiwan . The study aim evaluate clinical effect re-administration EGFR-TKI use retrospectively collect data eligible patient provide valuable information .</detailed_description>
	<criteria>1 . Patients diagnose advanced adenocarcinoma positive result thyroid transcription factor 1 NSCLC 2 . Positive Epidermal Growth Factor Receptor mutation result sensitive mutation 3 . Female male age â‰§20 year 4 . Patients treat Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor subsequently treat chemotherapy readministration Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor . 1 . Patients EGFR mutation status positive exon 20 T790M mutation . 2 . Patients confirm squamous type NSCLC</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>150 Years</maximum_age>
	<verification_date>November 2015</verification_date>
	<keyword>Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor retrement .</keyword>
</DOC>